COMPANY PROFILE // THE 014 REPORT
Freenome, Inc.
FRNM (Nasdaq) · Formerly: Perceptive Capital Solutions Corp
Assembled from 2 government sources in 4.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2026-07-24 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Freenome, Inc. is an SEC-registered operating company in services-medical laboratories, incorporated in DE, based in Brisbane, CA; listed as FRNM (Nasdaq).[source] It has filed 100 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Seraphix flags 1 item from these records: 8-K Item 4.01 filed.[source]
- red0
- amber1
- info0
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Legal counsel, as publicly named
- GOODWIN PROCTER LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-09-23
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0002017526 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | GENESIS MARINA, 3300 MARINA BLVD, BRISBANE, CA, 94005 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 8071 (services-medical laboratories): 29 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- Personalis, Inc. · 98 SEC filings in 12 months · 1 flag · $57.5M federal (possible match)
- Fulgent Genetics, Inc. · 86 SEC filings in 12 months · 2 flags · $19.8M federal (possible match)
- CareDx, Inc. · 125 SEC filings in 12 months · 2 flags · $18.6M federal (possible match)
- VERACYTE, INC. · 122 SEC filings in 12 months · 1 flag · $7.8M federal (possible match)
- QUEST DIAGNOSTICS INC · 130 SEC filings in 12 months · $3.9M federal (possible match)
- RadNet, Inc. · 71 SEC filings in 12 months · 1 flag · $76K federal (possible match)
- Natera, Inc. · 309 SEC filings in 12 months · 1 flag
- Guardant Health, Inc. · 258 SEC filings in 12 months · 2 flags
- LABCORP HOLDINGS INC. · 154 SEC filings in 12 months · 1 flag
- CASTLE BIOSCIENCES INC · 141 SEC filings in 12 months · 1 flag
- BillionToOne, Inc. · 140 SEC filings in 12 months
- SERA PROGNOSTICS, INC. · 138 SEC filings in 12 months · 1 flag
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing 424B3 · SEC EDGAR
- 2026-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-20 filing 424B3 · SEC EDGAR
- 2026-10-20 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-23 filing S-8 · SEC EDGAR
- 2026-08-27 filing EFFECT · SEC EDGAR
- 2026-08-27 filing 424B3 · SEC EDGAR
- 2026-08-18 filing Registration (S-1) · SEC EDGAR
- 2026-08-13 filing 8-K/A items 2.01,9.01 · SEC EDGAR
- 2026-07-29 filing EFFECT · SEC EDGAR
- 2026-07-28 filing POS AM · SEC EDGAR
- 2026-07-27 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-24 filing POS AM · SEC EDGAR
- 2026-07-24 officer change 8-K items 1.01,2.01,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01 · SEC EDGAR
- 2026-07-22 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-07-20 filing CERT · SEC EDGAR
- 2026-07-20 filing 25-NSE · SEC EDGAR
- 2026-07-20 filing 8-A12B · SEC EDGAR
- 2026-07-15 filing 425 · SEC EDGAR
- 2026-07-15 filing 8-K items 5.07 · SEC EDGAR
- 2026-07-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-15 name change Name changed from Perceptive Capital Solutions Corp · SEC EDGAR
- 2026-07-09 filing 424B3 · SEC EDGAR
- 2026-07-09 filing 425 · SEC EDGAR
- 2026-07-09 filing 425 · SEC EDGAR
- 2026-07-09 filing 425 · SEC EDGAR
- 2026-07-09 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-18 filing 425 · SEC EDGAR
- 2026-06-18 filing 8-K items 7.01,9.01 · SEC EDGAR
49 earlier entries
- 2026-06-17 filing EFFECT
- 2026-06-17 filing 424B4
- 2026-06-11 filing S-4/A
- 2026-06-11 filing S-4/A
- 2026-06-10 filing 425
- 2026-06-10 filing 8-K items 5.03,5.07,9.01
- 2026-06-01 filing S-4/A
- 2026-05-19 filing 425
- 2026-05-14 filing Proxy statement
- 2026-05-13 filing Quarterly report (10-Q)
- 2026-05-05 filing PRE 14A
- 2026-04-28 filing S-4
- 2026-04-13 filing 425
- 2026-03-30 filing DRS/A
- 2026-03-12 filing Annual report (10-K)
- 2026-03-02 filing 425
- 2026-01-12 filing DRS
- 2025-12-12 filing SCHEDULE 13D
- 2025-12-05 filing 425
- 2025-12-05 filing 425
- 2025-12-05 filing 425
- 2025-12-05 filing 425
- 2025-12-05 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-08-13 filing Quarterly report (10-Q)
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-03-19 filing Annual report (10-K)
- 2024-11-13 filing Quarterly report (10-Q)
- 2024-08-14 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K/A items 8.01,9.01
- 2024-06-20 filing 8-K items 8.01,9.01
- 2024-06-13 filing 8-K items 1.01,3.02,5.03,8.01,9.01
- 2024-06-12 filing 424B4
- 2024-06-11 filing EFFECT
- 2024-06-11 filing CERT
- 2024-06-10 filing CORRESP
- 2024-06-10 filing CORRESP
- 2024-06-10 filing CORRESP
- 2024-06-10 filing CORRESP
- 2024-06-10 filing 8-A12B
- 2024-06-07 filing CORRESP
- 2024-06-07 filing CORRESP
- 2024-06-07 filing CORRESP
- 2024-06-07 filing S-1/A
- 2024-06-07 filing UPLOAD
- 2024-05-21 filing CORRESP
- 2024-05-21 filing Registration (S-1)
- 2024-05-16 filing UPLOAD
- 2024-04-16 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 7 days) 424B3 filed
- 2026-11-12 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 (older) 424B3 filed
- 2026-10-20 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-23 (older) S-8 filed
- 2026-08-27 (older) EFFECT filed
- 2026-08-27 (older) 424B3 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:FRNM The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 2017526 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | FRNM / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 35661P100 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0002017526 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | $837,468 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:09 UTC | Report an error |
| Total assets (at 2025-12-31) | $92,779,988 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:09 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$4,796,674 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:09 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $865,031 | 2025-12-31 | 10-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | as filed | 2026-11-20 10:09 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
| SIC industry | 8071 Services-Medical Laboratories | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
| Business address | GENESIS MARINA, 3300 MARINA BLVD, BRISBANE, CA, 94005 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:09 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$864,653 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:09 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0002017526-26-000027
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $183,489,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
| Net income (loss) | $60,110,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
| Interest expense | $1,188,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
| Cash and cash equivalents | $180,379,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
| Contract liabilities, current | $0 | at 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
| Contract liabilities, noncurrent | $24,594,000 | at 2026-09-30 | 10-Q | 2026-11-12 | 0002017526-26-000027 | 2026-11-20 10:09 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 424B3 filed
- 2026-11-12 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 Filing 424B3 filed
- 2026-10-20 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-23 Filing S-8 filed
- 2026-08-27 Filing EFFECT filed
- 2026-08-27 Filing 424B3 filed
- 2026-08-18 Filing S-1 filed
- 2026-08-13 Filing 8-K/A filed: Item 2.01 acquisition or disposition; Item 9.01 exhibits
- 2026-07-29 Filing EFFECT filed
- 2026-07-28 Filing POS AM filed
- 2026-07-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-24 Filing POS AM filed
- 2026-07-24 Filing 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 3.02 unregistered equity sale; Item 3.03 rights of holders modified; Item 4.01 auditor change; Item 5.01 change in control; Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 5.05; Item 5.06; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-20 Filing CERT filed
- 2026-07-20 Filing 25-NSE filed
- 2026-07-20 Filing 8-A12B filed
- 2026-07-15 Filing 425 filed
- 2026-07-15 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-07-15 Filing 10-Q filed
- 2026-07-09 Filing 424B3 filed
- 2026-07-09 Filing 425 filed
- 2026-07-09 Filing 425 filed
- 2026-07-09 Filing 425 filed
8-K item text, as filed (excerpts)
- 2026-11-10 8-K Item 2.02, Results of Operations and Financial Condition
On November 10, 2026, Freenome, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed incorporated by reference… the 8-K · retrieved 2026-11-20 10:09 UTC - 2026-10-20 8-K Item 7.01
Regulation FD Disclosure On October 20, 2026, Freenome, Inc. (the “Company”) issued a press release titled “Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by… the 8-K · retrieved 2026-11-20 10:09 UTC - 2026-10-20 8-K Item 8.01
Other Events On October 20, 2026, the Company announced the launch of SimpleScreen™ Lung and a first-of-its-kind offering that enables eligible patients to be screened for both lung and colorectal cancer (“CRC”) through a single blood draw, using two independently validated, indication-specific tests. The Company’s Personalized Cancer Detection approach combines risk-based screening with a portfolio of single-cancer and multi-cancer tests that are developed specifically for each population and to meet individual patient screening needs. SimpleScreen Lung was clinically validated in a case-control study of adults ages 50 to 80 with a ≥20 pack-year smoking history who meet American Cancer… the 8-K · retrieved 2026-11-20 10:09 UTC - 2026-08-13 8-K Item 2.01
Completion of Acquisition or Disposition of Assets Financial Information Management’s Discussion and Analysis of Financial Condition and Results of Operations of Freenome for the three and six months ended June 30, 2026 and 2025 is set forth in Exhibit 99.2 to this Amendment No. 1, and is incorporated herein by reference. Quantitative and Qualitative Disclosures about Market Risk As a “smaller reporting company,” New Freenome is not required to provide this information. Financial Statements, Supplementary Data and Exhibits Reference is made to the information set forth in sections (a) and (b) of Item 9.01 of this Amendment No. 1 and is incorporated herein by reference. the 8-K · retrieved 2026-11-20 10:09 UTC - 2026-07-27 8-K Item 7.01, Regulation FD Disclosure
On July 27, 2026, Freenome, Inc. (the “Company”) issued a press release titled “FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or… the 8-K · retrieved 2026-11-20 10:09 UTC - 2026-07-27 8-K Item 8.01, Other Events
On July 27, 2026, the Company announced that the U.S. Food and Drug Administration (“FDA”) has approved SimpleScreen™ CRC, a new blood-based screening option for colorectal cancer (“CRC”) in adults 45 and older who are at average risk for the disease. Colorectal cancer is the second-leading cause of cancer-related death in the U.S., but it is highly preventable and treatable when detected early through screening. Up to 60 million Americans remain overdue for recommended screening, underscoring the need for additional convenient screening approaches that can help reach more people. SimpleScreen CRC detects signals associated with colorectal cancer from cell-free DNA in the blood. FDA… the 8-K · retrieved 2026-11-20 10:09 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/2017526.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0002017526. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.